modelLabetalol

Diagram of Labetalol

Extends from Pharmacolibrary.Drugs.ATC.C.C07AG01.

Information

name:Labetalol
ATC code:C07AG01
route:intravenous
compartments:2
dosage:20mg
volume of distribution:8.3L
clearance:336ml/min
other parameters in model implementation

Labetalol is a combined alpha- and beta-adrenergic receptor antagonist used primarily for the treatment of hypertension, including hypertensive emergencies and chronic hypertension. It is approved for clinical use and is widely prescribed today.

Pharmacokinetics

Pharmacokinetic parameters derived from healthy adult volunteers after a single intravenous dose.

References

  1. Chera-Aree, P, et al., & Wataganara, T (2020). Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. Journal of clinical pharmacology 60(12) 1662–1670. DOI:10.1002/jcph.1685 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32598488

  2. Hafsa, H, et al., & Alqahtani, F (2022). Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations. Pharmaceutics 14(11) –. DOI:10.3390/pharmaceutics14112362 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36365181

  3. Rasmussen, BB, et al., & Senderovitz, T (2005). Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers. BJOG : an international journal of obstetrics and gynaecology 112(11) 1492–1499. DOI:10.1111/j.1471-0528.2005.00735.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16225568

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)